Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$120.56 USD
-1.10 (-0.90%)
Updated May 6, 2024 04:00 PM ET
After-Market: $120.59 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZBH 120.56 -1.10(-0.90%)
Will ZBH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZBH
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline
Other News for ZBH
Zimmer Biomet Publishes 2023 Sustainability Report
Zimmer Biomet Holdings: A Cautious Hold Amid Competitive Market Challenges and Mixed Financial Results
Zimmer Biomet price target lowered by $7 at Truist, here's why
Zimmer Biomet price target raised by $5 at Oppenheimer, here's why
Oppenheimer Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)